| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.41▼ | 2.41▼ | 2.42▼ | 2.37▲ | 2.37▲ |
| MA10 | 2.41▼ | 2.41▼ | 2.41▼ | 2.32▲ | 2.37▲ |
| MA20 | 2.41▼ | 2.40▼ | 2.38▲ | 2.34▲ | 2.34▲ |
| MA50 | 2.41▼ | 2.38▲ | 2.36▲ | 2.36▲ | 1.95▲ |
| MA100 | 2.39▲ | 2.35▲ | 2.32▲ | 2.32▲ | 1.61▲ |
| MA200 | 2.37▲ | 2.33▲ | 2.38▲ | 2.18▲ | 1.57▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.002▼ | 0.001▲ | 0.011▲ | -0.023▼ |
| RSI | 41.452▼ | 51.987▲ | 55.171▲ | 53.003▲ | 54.862▲ |
| STOCH | 58.333 | 57.692 | 77.011 | 71.795 | 46.681 |
| WILL %R | -60.000 | -53.846 | -30.435 | -25.641 | -55.385 |
| CCI | -267.901▼ | -80.241 | 26.083 | 87.211 | -2.018 |
|
Wednesday, February 11, 2026 04:44 AM
Spero Therapeutics’ oral antibiotic tebipenem shows Phase 3 success and supports GSK’s NDA resubmission. Click here to read my latest analysis of SPRO stock.
|
|
Friday, December 19, 2025 04:59 AM
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare ...
|
|
Friday, November 28, 2025 05:00 AM
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics (SPRO), Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/02/26 | 2.38 | 2.4366 | 2.38 | 2.39 | 136,759 |
| 12/02/26 | 2.37 | 2.41 | 2.315 | 2.38 | 104,212 |
| 11/02/26 | 2.37 | 2.4294 | 2.32 | 2.37 | 138,164 |
| 10/02/26 | 2.40 | 2.40 | 2.35 | 2.36 | 173,628 |
| 09/02/26 | 2.40 | 2.40 | 2.275 | 2.36 | 349,226 |
| 06/02/26 | 2.31 | 2.43 | 2.305 | 2.42 | 1,027,764 |
| 05/02/26 | 2.25 | 2.49 | 2.25 | 2.30 | 748,657 |
| 04/02/26 | 2.26 | 2.32 | 2.185 | 2.29 | 937,763 |
| 03/02/26 | 2.21 | 2.29 | 2.10 | 2.14 | 440,521 |
| 02/02/26 | 2.15 | 2.265 | 2.138 | 2.23 | 277,128 |
|
|
||||
|
|
||||
|
|